Vaccines-2013 - OMICS Group

Recommendations

Info

Nisha N et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USATetravalent protein vaccine against Staphylococcus aureusNisha N and Raja BiswasAmrita Centre for Nanosciences and Molecular Medicine, IndiaStaphylococcus aureus causes wide range of diseases from minor infections to life-threatening sepsis, endocarditis, andpneumonia. Several antigens have been identified so far as vaccine that, either alone or in combination have the ability toreduce S. aureus (including multi drug resistant strains) colonization in animal models but with little success. Here we exploredthe possibility of designing a vaccine based on non-covalently surface associated proteins (NCSPs) of S. aureus. The knownNCSPs proteins [GM, Aaa, LytM, IsaB, SEM, SsA, Amidase( AM), LytR, LytN ,and SAV-1056] were cloned and expressed in E.coli as N-terminal histidine tagged protein and purified using Ni-NTA chromatography. The antigenicity of these proteins wastested against sera from S. aureus infected mice using ELISA and immunogenicity tested using mice splenocyte proliferationassay. All the NCSPs were antigenic and immunogenic; however the degree differed among NCSPs. The shortlisted proteins, withhigh homology score across different S. aureus strains, were used for vaccination study in BALB/c mice. The selected proteinswere found to trigger Th1 response in splenocyte proliferation assay. Upon vaccination with a cocktail of NSCPs in BALB/cmice, we observed that all the vaccinated mice survived till the 9th day, and 6 survived till day 14 (75% survival). Only 1 out of 8non-vaccinated mice survived after lethal challenge with S. aureus. There was 6-7 fold reduction in the bacterial load in internalorgans of vaccinated mice. The sera of the vaccinated mice were capable of inducing opsonophagocytosis of S. aureus by humanpolymorphonuclear leukocytes.BiographyNisha N is currently undergoing her Ph.D. program in the fi eld of Infectious diseases at Amrita Center for Nanosciences and Molecular medicine,AIMS, Kochi. She has been awarded with Senior Research Fellowship by Indian Council of Medical Research, India. She has two second authorpublications to her credit and her main work yet to be published.nishaaa.n@gmail.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 104
Yurong Tan et al., J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0173 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAAn inactivated Pseudomonas aeruginosa vaccine restores imbalanced airway immunityYurong Tan, LiLi wang, Dan Peng, Huihui Yang and Xiaoqun QinCentral South University, ChinaObjectives: Previously, we observed that an inactivated Pseudomonas aeruginosa vaccine (PPA) which was obtained bytransfection with the adhesion portion of type 1 fimbria of avian pathogenic E. coli inhibited airway allergic inflammationby bronchial administration in an OVA-induced airway hyperresponsiveness animal model. To investigate the underlyingmechanism involved, we studied the effects of PPA on epithelial functions in present studies by OVA stress or RSV infection.Methods: Flow cytometry was used to observe the effects of PPA on cell proliferation of BECs and BECs-drived subsets’differentiation of CD4+T cells. Real-time PCR was used to test the expressions of toll like receptor 4 and 5, two recognizedasthmatic therapeutic targets IL-17A/Th2 signal molecules Act1 and NF-kB negative regulator A20 in BECs.Results: PPA can promote cell proliferation and toll like receptor-4 and 5 expressions of normal, OVA-stressed and RSV-infectedBECs. PPA inhibited Th2 and Th17 differentiation and stimulated Th1 differentiation induced by OVA or RSV. PPA significantlydecreased Act1 expression induced by OVA and increased Act1 expression in BECs inhibited by RSV infection. PPA significantlyincreased A20 expression in BECs inhibited by OVA or RSV.Conclusions: Our data suggest that the therapeutic mechanism of PPA is partly to promote bronchial proliferation and shiftbronchial immunity from a Th2 and Th17 to a Th1 bias.Keywords: Pseudomonas aeruginosa, toll like receptors, RSV, CD4+T cells.hope7@126.comJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 105
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22:
Virology-2013OMICS Group is organiz
Page 23 and 24:
Page 25 and 26:
Because of heightened awareness of
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36:
Nikolai Petrovsky, J Vaccines Vacci
Page 37 and 38:
Page 39 and 40:
Robert E. Sievers et al., J Vaccine
Page 41 and 42:
Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44:
Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46:
Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48:
Diane Longo et al., J Vaccines Vacc
Page 49 and 50:
Track 33: Novel Approaches in Desig
Page 51 and 52:
Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71 and 72: Gisela Gonzalez, J Vaccines Vaccin
Page 73 and 74: Young Research ForumSession ChairPe
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 95 and 96: 111 th OMICS Group Conference3 rd I
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103: Ates Kara et al., J Vaccines Vaccin
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124: Aleksandar Masic et al., J Vaccines
Page 125 and 126: Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128: Oladipo Aina et al., J Vaccines Vac
Page 129 and 130: Aiswariya Chidambaram, J Vaccines V
Page 131 and 132: Birhanu Hurisa et al., J Vaccines V
Page 133 and 134: Ghaffarifar F et al., J Vaccines Va
Page 135 and 136: Mathan Periasamy et al., J Vaccines
Page 137 and 138: Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140: Samuel Teshome, J Vaccines Vaccin 2
Page 143 and 144: Birhanu Hurisa et al., J Vaccines V
Page 145 and 146: Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148: Belachew Etana et al., J Vaccines V
Page 149 and 150: Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152: Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154: Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?